Review: Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension

Abstract

Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications. Calcium antagonists (CAs) and blockers of the renin-angiotensin system [angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists (ARBs)] are widely used today to initiate antihypertensive treatment but, when given as monotherapy, do not suffice in most patients to normalise blood pressure (BP). Combining a CA and either an ACE-inhibitor or an ARB considerably increases the antihypertensive efficacy, but not at the expense of a deterioration of tolerability. Several fixed-dose combinations are available (CA + ACE-inhibitors: amlodipine + benazepril, felodipine + ramipril, verapamil + trandolapril; CA + ARB: amlodipine + valsartan). They are expected not only to improve BP control, but also to facilitate long-term adherence with ON antihypertensive therapy, thereby providing renal damage caused by high BP. maximal protection against the cardiovascular and renal damage caused by high BP.

Keywords

angiotensin-converting enzyme inhibitors angiotensin II antagonists calcium antagonists guidelines hypertensin tolerability

Get full access to this article

View all access options for this article.

References

He J. , Whelton PK Epidemiology and prevention of hypertension. Med Clin North Am 1997;81:1077-97.

Ezzati M. , Lopez AD , Rodgers A. , Vander Hoorn S. , Murray CJ Selected major risk factors and global and regional burden of disease . Lancet 2002;360:1347-60.

Kearney PM , Whelton M. , Reynolds K. , Whelton PK , He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-19.

Turnbull F. , Neal B. , Algert C. et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomised trials . Arch Intern Med 2005;165:1410-19.

Staessen JA , Li Y. , Thijs L. , Wang JG Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407.

Dickerson CJE , Hingorani AD , Ashby MJ , Palmer CR , Brown MJ Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;288:2977-81.

Dahlöf B. , Devereux RB , Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention. For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.

Pepine CJ , Handberg EM , Cooper-DeHoff RM et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.

10.

Julius S. , Kjeldsen SE , Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial . Lancet 2004;363:2022-31. 11. Dahlöf B. , Sever PS , Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.

11.

Law MR , Wald NJ , Morris JK , Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003 ;326:1427-31.

12.

Dezii CM A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managing Care 2000;9 (suppl.):2-6.

13.

Chobanian AV , Bakris GL , Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.

14.

Mancia G. , De Backer G. , Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.

15.

Abernethy DR , Schwartz JB Calcium-antagonist drugs. N Engl J Med 1999;341:1447-57.

16.

Luscher TF , Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998;55:509-17.

17.

Grossman E. , Messerli FH Calcium antagonists. Progress Cardiovasc Dis 2004;47:34-57.

18.

McEwan JR , Fuller RW Angiotensin converting enzyme inhibitors and cough. J Cardiovasc Pharmacol 1989;13(suppl 3):S67-69.

19.

Grossman E. , Messerli FH Long-term safety of antihypertensive therapy . Progress Cardiovasc Dis 2006;49:16-25.

20.

Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005;45:813-27.

21.

Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. JRAAS 2006;7:61-3.

22.

Mancia G. , Dell'Oro R. , Quasrti-Trevano F. , Scopelliti F. , Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens 2006;24 (suppl 1):51-6.

23.

Folkow, B. A Physiological aspects of primary hypertension. Phys Rev 1982;62:347-504.

24.

Staessen JA , Wang J. , Bianchi G. , Birkenhager WH Essential hypertension . Lancet 2003;361:1629-41.

25.

Beevers DG , Sleight P.

Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?

BMJ 1996 ;312:1143-45.

26.

Grossman E. , Messerli FH Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997;80:1453-8.

27.

Binggeli C. , Corti R. , Sudano I. , Luscher TF , Noll G. Noll G. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39:892-6.

28.

Niarchos AP , Pickering TG , Morganti A. , Laragh JH Plasma catecholamines and cardiovascular responses during converting enzyme inhibition in normotensive and hypertensive man. Clin Exper Hypertens 1982;4:761-89.

29.

Seljeflot I. , Moan A. , Kjeldsen S. , Sandvik E. , Arnesen H. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension . Hypertension 1996;27:1299-304.

30.

Miyajima E. , Shigemasa T. , Yamada Y. , Tochikubo O. , Ishii M. Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol 1999;26:797-802.

31.

Sturani A. , Chiarini C. , Degliesposti E. , Santoro A. , Zuccala A. , Zucchelli P. Heart rate control in hypertensive patients treated by captopril. Br J Clin Pharmacol 1982;14:849-55.

32.

Pancera P. , Presciuttini B. , Sansone S. et al. Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. J Hypertens 1999;17:513-21.

33.

Kuschnir E. , Acuna E. , Sevilla D. et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996;18:1213-24.

34.

Karlberg BE , Andrup MAO. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Blood Pressure 2000 ;9:140-5.

35.

Messerli FH , Oparil S. , Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182-7.

36.

Pool J. , Kaihlanen P. , Lewis G. et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs. amlodipine or benazepril alone. J Hum Hypertens 2001;15:495-98.

37.

Messerli FH , Weir MR , Neutel JM Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002;15:550-6.

38.

Jamerson KA , Nwose O. , Jean-Louis L. , Schofield L. , Purkayastha D. , Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension . Am J Hypertens 2004;17:495-501.

39.

Philipp T. , Smith TR , Glazer R. et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80.

40.

Neutel JM , Smith DH , Weber MA Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004;17:37-42.

41.

Hasebe N. , Kikuchi K. , NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study . J Hypertens 2005;23:445-53.

42.

Luscher TF , Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial . J Cardiovasc Pharmacol 1993;21:305-09.

43.

Letellier P. , Overlack A. , Agnes E. , Desche P. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. J Hum Hypertens 1994;8:145-9.

44.

de Leeuw PW , Notter T. , Zilles P. Comparison of different fixed antihypertensive combination drug : a double-blind, placebocontrolled parallel group study . J Hypertens 1997;15:87-91. 46. Weir MR , Weber MA , Neutel JM , Vendetti J. , Michelson EL ,

45.

Wang wRY .Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001;14:567-72.

46.

Agrawal R. , Marx A. , Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension . Hypertens 2006;24:185-92.

47.

Poldermans D. , Glazes R. , Kargiannis S. et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007 ;29:279-89.

48.

Gennari C. , Nami R. , Pavese G. , Gragnani S. , Bianchini C. , Buracchi P. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drug Ther 1989;3(suppl 1):319-25.

49.

Messerli FH Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Reports 2002;4:479-82.

50.

Weir MR , Rosenberger C. , Fink JC Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001;14:963-8.

51.

Fogari R. , Zoppi A. , Derosa G. et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4.

52.

Waeber B. , Burnier M. , Brunner HR Compliance with antihypertensive therapy. Clin Exper Hypertens 1999;21:973-85.

53.

Taylor AA , Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003;9:324-32.

54.

Lithell HO Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism . Diabetes Care 1991;14:203-09. 56. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12.

55.

Jandeleit-Dahm KA , Tikellis C. , Reid CM , Johnston CI , Cooper ME Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-73.

56.

Elliott WJ , Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369: 201-07

57.

Bakris G. , Molitch M. , Hewkin A. et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7.

58.

Bakris GL , Gaxiola E. , Messerli FH et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 2004;44:637-42.

59.

Mancia G. , Messerli F. , Bakris G. , Zhou Q. , Champion A. , Pepine CJ Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007;50:299-305.

60.

Cooper-Dehoff R. , Cohen JD , Bakris GL et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006;98:890-4.

61.

Poulter NR , Wedel H. , Dahlof B. et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13.

62.

O'Rourke M. Mechanical principles in arterial disease . Hypertension 1995;26:2-9.

63.

Williams B. , Lacy PS , Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.

64.

Jamerson KA , Bakris GL , Wun CC et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801.

65.

Jamerson K. , Bakris GL , Dahlof B. et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Pressure 2007;16:80-6.